• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肺癌患者静脉血栓栓塞症的患病率及临床特征：一项系统评价和荟萃分析。

Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.

作者信息

Xu Ying, Wu Tong, Ren Xue, Liu Jing, Zhang Haibo, Yang Defu, Yan Ying, Lv Dongyang

机构信息

Department of Radiation Oncology, General Hospital of Northern Theater Command, Shenyang, China.

出版信息

Front Oncol. 2024 Aug 14;14:1405147. doi: 10.3389/fonc.2024.1405147. eCollection 2024.

DOI:10.3389/fonc.2024.1405147
PMID:39206158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11350514/
Abstract

BACKGROUND

The prevalence of venous thromboembolism (VTE) is high in patients with cancer and can often present as the first symptom of malignancy. Cancer-associated VTE is one of the most important risk factors contributing to cancer mortality, making its prevention and treatment critical for patients with lung cancer.

METHODS

We systematically searched for observational studies that estimated the prevalence of VTE in patients with lung cancer. A comprehensive search of electronic databases, including PubMed, EMBASE and Cochrane Library, was systematically conducted from database inception through January 21, 2022. The qualities of included studies were assessed in three domains, including patient selection, comparison, and results. Random effects meta-analyses of the prevalence of VTE in lung cancer were conducted using the metaprop procedure. Chi-square test and value were used to evaluate study heterogeneity.

RESULTS

Thirty-five studies involving 742,156 patients were considered eligible for this study. The pooled prevalence of VTE among patients with lung cancer was 5% (95% CI: 0.043-0.056, = 0.000). The regional prevalence of VTE was 7% (95% CI: 0.06-0.08; I 99.2%) in North America, 8% (95% CI: 0.06-0.10; I 97.6%) in Asia, 6% (95% CI: 0.04-0.09; I 95.9%) in Europe and 11% (95% CI: 0.07-0.15) in Australasia.

CONCLUSIONS

The prevalence of lung cancer-related VTE is high and region-specific. These results of this review emphasize the importance of understanding the incidence of lung cancer-related VTE and provide argue for VTE screening of patients with lung cancer.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/prospero/, identifier PROSPERO (CRD42022306400).

摘要

背景

静脉血栓栓塞症（VTE）在癌症患者中患病率较高，且常可作为恶性肿瘤的首发症状。癌症相关的VTE是导致癌症死亡的最重要危险因素之一，因此其预防和治疗对肺癌患者至关重要。

方法

我们系统检索了估计肺癌患者VTE患病率的观察性研究。从数据库建立至2022年1月21日，系统全面地检索了电子数据库，包括PubMed、EMBASE和Cochrane图书馆。纳入研究的质量从患者选择、对照和结果三个方面进行评估。采用metaprop程序对肺癌患者VTE的患病率进行随机效应荟萃分析。使用卡方检验和I²值评估研究的异质性。

结果

35项涉及742156例患者的研究被认为符合本研究的条件。肺癌患者中VTE的合并患病率为5%（95%CI：0.043 - 0.056，I² = 0.000）。VTE的地区患病率在北美为7%（95%CI：0.06 - 0.08；I² = 99.2%），在亚洲为8%（95%CI：0.06 - 0.10；I² = 97.6%），在欧洲为6%（95%CI：0.04 - 0.09；I² = 95.9%），在澳大拉西亚为11%（95%CI：0.07 - 0.15）。

结论

肺癌相关VTE的患病率较高且具有地区特异性。本综述的这些结果强调了了解肺癌相关VTE发病率的重要性，并为肺癌患者的VTE筛查提供了依据。

系统评价注册

https://www.crd.york.ac.uk/prospero/，标识符PROSPERO（CRD42022306400）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/0ed45055c351/fonc-14-1405147-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/c2499ad781b5/fonc-14-1405147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/d759c563af33/fonc-14-1405147-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/7dca47ecc1e2/fonc-14-1405147-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/bd10507cf2eb/fonc-14-1405147-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/377509dddc18/fonc-14-1405147-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/d1202656ced4/fonc-14-1405147-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/9ce19c2842e1/fonc-14-1405147-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/73e3722ddf63/fonc-14-1405147-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/5670719fdf6e/fonc-14-1405147-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/317405d81de3/fonc-14-1405147-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/28968c5723b4/fonc-14-1405147-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/20b6db2297f0/fonc-14-1405147-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/da2d3d6537fe/fonc-14-1405147-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/0ed45055c351/fonc-14-1405147-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/c2499ad781b5/fonc-14-1405147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/d759c563af33/fonc-14-1405147-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/7dca47ecc1e2/fonc-14-1405147-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/bd10507cf2eb/fonc-14-1405147-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/377509dddc18/fonc-14-1405147-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/d1202656ced4/fonc-14-1405147-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/9ce19c2842e1/fonc-14-1405147-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/73e3722ddf63/fonc-14-1405147-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/5670719fdf6e/fonc-14-1405147-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/317405d81de3/fonc-14-1405147-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/28968c5723b4/fonc-14-1405147-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/20b6db2297f0/fonc-14-1405147-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/da2d3d6537fe/fonc-14-1405147-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aac3/11350514/0ed45055c351/fonc-14-1405147-g014.jpg

相似文献

1
Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.肺癌患者静脉血栓栓塞症的患病率及临床特征：一项系统评价和荟萃分析。
Front Oncol. 2024 Aug 14;14:1405147. doi: 10.3389/fonc.2024.1405147. eCollection 2024.
2
Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study.跨性别者接受激素 feminizing 治疗后的静脉血栓栓塞风险：一项患病率的荟萃分析和荟萃回归研究。
Front Endocrinol (Lausanne). 2021 Nov 9;12:741866. doi: 10.3389/fendo.2021.741866. eCollection 2021.
3
Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.对有静脉血栓栓塞风险的住院患者实施血栓预防的干预措施。
Cochrane Database Syst Rev. 2018 Apr 24;4(4):CD008201. doi: 10.1002/14651858.CD008201.pub3.
4
Prognostic value of venous thromboembolism in patients with advanced pancreatic cancer: a systematic review and meta-analysis.晚期胰腺癌患者静脉血栓栓塞的预后价值：一项系统评价和荟萃分析
Front Oncol. 2024 Feb 8;14:1331706. doi: 10.3389/fonc.2024.1331706. eCollection 2024.
5
Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis.慢性肝脏疾病中静脉血栓栓塞症的发病率和患病率：系统评价和荟萃分析。
Thromb Res. 2022 Jul;215:19-29. doi: 10.1016/j.thromres.2022.05.004. Epub 2022 May 17.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.首次无诱因静脉血栓栓塞事件停止抗凝治疗后症状性复发性静脉血栓栓塞的长期风险：系统评价和荟萃分析。
BMJ. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363.
8
Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis.肝病患者静脉血栓栓塞症的流行病学：一项系统评价和荟萃分析。
Intern Emerg Med. 2015 Mar;10(2):205-17. doi: 10.1007/s11739-014-1163-7. Epub 2014 Dec 4.
9
Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis.他汀类药物对复发性静脉血栓栓塞风险的影响：系统评价和荟萃分析。
Pharmacol Res. 2021 Mar;165:105413. doi: 10.1016/j.phrs.2020.105413. Epub 2021 Jan 5.
10
Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis.炎症性免疫疾病中使用 Janus 激酶抑制剂引发静脉血栓栓塞的风险：一项系统评价与荟萃分析
Front Pharmacol. 2023 Jun 7;14:1189389. doi: 10.3389/fphar.2023.1189389. eCollection 2023.

引用本文的文献

1
The incidence and risk factors of venous thromboembolism in patients with pancreatic cancer: a systematic review and meta-analysis.胰腺癌患者静脉血栓栓塞的发生率及危险因素：一项系统评价和荟萃分析
J Gastrointest Oncol. 2025 Aug 30;16(4):1667-1681. doi: 10.21037/jgo-2025-132. Epub 2025 Aug 27.
2
Coagulation Abnormalities in Lung Cancer: Diagnostic Challenges and Therapeutic Perspectives.肺癌中的凝血异常：诊断挑战与治疗前景
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251359293. doi: 10.1177/10760296251359293. Epub 2025 Aug 18.

本文引用的文献

1
The Interplay of Race/Ethnicity and Obesity on the Incidence of Venous Thromboembolism.种族/民族和肥胖对静脉血栓栓塞发生率的相互影响。
Am J Prev Med. 2022 Jul;63(1):e11-e20. doi: 10.1016/j.amepre.2021.12.023. Epub 2022 Mar 5.
2
Venous Thromboembolism in Surgical Lung Cancer Patients: A Provincial Population-Based Study.外科肺癌患者的静脉血栓栓塞症：省级基于人群的研究。
Ann Thorac Surg. 2022 Sep;114(3):890-897. doi: 10.1016/j.athoracsur.2021.10.018. Epub 2021 Nov 14.
3
Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
《癌症相关静脉血栓栓塞性疾病》，2021年第2版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南
J Natl Compr Canc Netw. 2021 Oct 15;19(10):1181-1201. doi: 10.6004/jnccn.2021.0047.
4
Venous and Arterial Thromboembolism in Patients With Cancer: : State-of-the-Art Review.癌症患者的静脉和动脉血栓栓塞：最新综述
JACC CardioOncol. 2021 Apr 20;3(2):173-190. doi: 10.1016/j.jaccao.2021.03.001. eCollection 2021 Jun.
5
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.免疫检查点抑制剂治疗非小细胞肺癌患者的静脉血栓栓塞事件：一项回顾性多中心队列研究。
Thromb Res. 2021 Sep;205:29-39. doi: 10.1016/j.thromres.2021.06.018. Epub 2021 Jun 29.
6
Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer.小细胞肺癌患者静脉血栓栓塞的风险因素。
Anticancer Res. 2021 Mar;41(3):1523-1528. doi: 10.21873/anticanres.14911.
7
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明：系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
8
Summarising good practice guidelines for data extraction for systematic reviews and meta-analysis.总结系统评价和荟萃分析数据提取的良好实践指南。
BMJ Evid Based Med. 2021 Jun;26(3):88-90. doi: 10.1136/bmjebm-2020-111651. Epub 2021 Feb 25.
9
The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery.肺癌手术患者术前深静脉血栓形成的发生率及相关危险因素。
Surg Today. 2021 Sep;51(9):1480-1487. doi: 10.1007/s00595-021-02243-3. Epub 2021 Feb 21.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.